GMT Capital Corp Sells 543,900 Shares of NewAmsterdam Pharma (NASDAQ:NAMS)

GMT Capital Corp decreased its holdings in NewAmsterdam Pharma (NASDAQ:NAMS - Free Report) by 65.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 285,136 shares of the company's stock after selling 543,900 shares during the quarter. NewAmsterdam Pharma comprises approximately 0.4% of GMT Capital Corp's portfolio, making the stock its 27th biggest position. GMT Capital Corp owned 0.31% of NewAmsterdam Pharma worth $7,328,000 as of its most recent SEC filing.

A number of other hedge funds have also added to or reduced their stakes in NAMS. Slate Path Capital LP purchased a new stake in shares of NewAmsterdam Pharma in the 4th quarter worth about $8,198,000. Rock Springs Capital Management LP lifted its holdings in NewAmsterdam Pharma by 117.2% in the fourth quarter. Rock Springs Capital Management LP now owns 767,522 shares of the company's stock worth $19,725,000 after buying an additional 414,203 shares during the period. Bain Capital Life Sciences Investors LLC boosted its position in NewAmsterdam Pharma by 2.3% during the 4th quarter. Bain Capital Life Sciences Investors LLC now owns 10,719,110 shares of the company's stock valued at $275,481,000 after acquiring an additional 245,197 shares in the last quarter. Capital World Investors purchased a new position in shares of NewAmsterdam Pharma during the 4th quarter worth approximately $26,113,000. Finally, Capital International Investors bought a new position in shares of NewAmsterdam Pharma in the 4th quarter worth approximately $53,007,000. 89.89% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CAO Louise Frederika Kooij sold 150,000 shares of NewAmsterdam Pharma stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $20.37, for a total value of $3,055,500.00. Following the completion of the sale, the chief accounting officer now owns 15,000 shares of the company's stock, valued at $305,550. The trade was a 90.91 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director James N. Topper acquired 4,005 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, March 4th. The shares were purchased at an average price of $21.02 per share, with a total value of $84,185.10. Following the transaction, the director now owns 3,012,434 shares of the company's stock, valued at $63,321,362.68. The trade was a 0.13 % increase in their position. The disclosure for this purchase can be found here. Insiders own 19.50% of the company's stock.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on NAMS shares. Royal Bank of Canada reaffirmed an "outperform" rating and issued a $40.00 price target on shares of NewAmsterdam Pharma in a research note on Friday, January 24th. Scotiabank increased their price target on shares of NewAmsterdam Pharma from $47.00 to $52.00 and gave the stock a "sector outperform" rating in a research note on Thursday, February 27th. HC Wainwright reissued a "buy" rating and set a $48.00 price target on shares of NewAmsterdam Pharma in a research report on Tuesday, January 14th. Needham & Company LLC restated a "buy" rating and issued a $42.00 price objective on shares of NewAmsterdam Pharma in a report on Tuesday, April 8th. Finally, UBS Group set a $41.00 target price on shares of NewAmsterdam Pharma in a report on Monday, March 3rd. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and an average price target of $43.33.

NewAmsterdam Pharma Stock Performance

Shares of NAMS traded up $0.23 on Monday, hitting $17.75. 94,977 shares of the stock traded hands, compared to its average volume of 592,667. The company has a market capitalization of $1.95 billion, a PE ratio of -6.80 and a beta of -0.01. NewAmsterdam Pharma has a one year low of $14.06 and a one year high of $27.29. The business has a 50 day simple moving average of $19.61 and a 200 day simple moving average of $21.24.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last posted its quarterly earnings results on Wednesday, February 26th. The company reported ($0.95) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.47). The firm had revenue of $12.77 million during the quarter, compared to analysts' expectations of $3.30 million. On average, equities analysts expect that NewAmsterdam Pharma will post -1.75 earnings per share for the current year.

NewAmsterdam Pharma Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.